Stock Taper
BYSI
BEYONDSPRING INC.
NASDAQ
$0.67
▲ UP 3.94% (0.03)

KEY STATISTICS

Market Cap$27.36 M
52w High$2.44
52w Low$0.57
Dividend Yield
Frequency
P/E-3.86
Volume113.57K
Shares Out.41.12M

COMPANY

LEADERSHIP

Qiu Min
CHIEF EXECUTIVE
Qiu Min

ABOUT

SECTOR
Healthcare
WENT PUBLIC
March 9, 2017
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
44

UPCOMING EARNINGS

DateNov 12, 2026
DayThursday
Rev. Est.$8.77M
NOV
12
THU

PRICE

$0.67 ▲ UP 3.94% (+$0.03)
$0.62$0.64$0.669:30 AM10:35 AM11:40 AM12:45 PM1:49 PM2:54 PM3:59 PM0.67

About BeyondSpring Inc.

https://www.beyondspringpharma.com ↗

BeyondSpring Inc. is a clinical-stage biopharma focused on cancer therapies, with lead drug Plinabulin in Phase III for chemo-induced neutropenia and NSCLC, plus ongoing immuno-oncology combination research.

INDUSTRY

Biotechnology

A PRODUCT BEYONDSPRING INC. IS KNOWN FOR

Plinabulin
Plinabulin

Plinabulin, BeyondSpring's lead immunomodulating microtubule-binding agent, is in late-stage trials for NSCLC and chemotherapy-induced neutropenia, showing promising combination therapy results.

COMPETITORS

RATINGS SNAPSHOT

Overall rating: C+

DCFROEROAD/EP/EP/B
Discounted Cash Flow3
Return On Equity5
Return On Assets1
Debt To Equity1
Price To Earnings1
Price To Book1
Overall Score2

INSIDER TRADES

OFFICER: CHIEF EXECUTIVE OFFICER
Qiu Min
· —
2026-07-01
OFFICER: CHIEF EXECUTIVE OFFICER
Qiu Min
Purchase · 100.0K shares
2026-07-01
Li Na (NL)
· —
2026-07-01
DIRECTOR
Majeti Jiangwen
Purchase · 100.0K shares
2026-07-01

SECTORS PEERS

PEERPRICE
ALXO$2.00COMPARE
UNCY$5.26COMPARE
BMEA$1.73COMPARE
GUTS$0.66COMPARE
DTIL$7.78COMPARE
CAMP$4.15COMPARE
HYFT$1.39COMPARE
ATYR$0.54COMPARE